AzTrials
AzTrials

Total Hip ArthroplastyNCT04145921

Effectiveness of Fast-track Clinical Pathway on Minimally-invasive Total Hip Arthroplasty Surgery in NTUH

A study testing ERAS for MIS-THA and conventional MIS-THA in people with Total Hip Arthroplasty, run by National Taiwan University Hospital.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of this study was to evaluate the effects of an enhanced recovery after surgery (ERAS) pathway incorporated with pre-operative physical therapy and education on immediate and short-term outcomes of minimally-invasive surgery of total hip arthroplasty (MIS-THA). Read more about this study

Who is it for?
Any age
Conditions the study is for
Total Hip Arthroplasty
What is being tested?
ERAS for MIS-THA and conventional MIS-THA
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
75 participants
Where
No sites listed yet
Study dates
7 Jan 2014to 28 Aug 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • patients with advanced osteonecrosis of femoral head or hip osteoarthritis receiving unilateral primary minimally-invasive surgery of total hip arthroplasty (MIS-THA) performed by the same surgeon at the same hospital

Who cannot join

  • patients with renal or hepatic function impairment which precluded multimodal pain control

About this study

The objective of this study was to evaluate the effects of an enhanced recovery after surgery (ERAS) pathway incorporated with pre-operative physical therapy and education on immediate and short-term outcomes of minimally-invasive surgery of total hip arthroplasty (MIS-THA). We hypothesized that this ERAS pathway can shorten post-operative length of hospital stay and ensure same-day independent mobilization in MIS-THA. The first specific aim was to compare primary immediate outcomes, including post-operative length of hospital stay and the rate of same-day independent mobilization, between ERAS for MIS-THA patients and conventional MIS-THA patients. The second aim was to compare other immediate outcomes, including post-operative pain scores, analgesics usage, the rate of blood transfusion and post-operative nausea and vomiting (PONV), between the two groups of patients. Third, we aimed to compare short-term outcomes, including post-operative 1-year Harris hip score, Oxford hip score and EQ-5D index of quality of life, between the two groups of patients. We also compared hospital cost and profit between the two groups of patients. Moreover, we identified the factors affecting post-operative length of hospital stay in ERAS for MIS-THA patients.

Read the detailed description

Study subjects:

We conducted a prospective comparative study to investigate 50 patients receiving an ERAS pathway incorporated with pre-operative physical therapy and education for MIS-THA and 25 patients receiving conventional MIS-THA. We included the patients with advanced osteonecrosis of femoral head or hip osteoarthritis receiving unilateral primary MIS-THA performed by the same surgeon at the same hospital. We excluded patients with renal or hepatic function impairment which precluded multimodal pain control. However, we did not preselect patients with younger age or better activity level. This study was approved by the Institutional Review Board at National Taiwan University Hospital. Written informed consent was obtained from all patients.

ERAS for MIS-THA versus conventional MIS-THA:

In this study, ERAS for MIS-THA was defined as the ERAS pathway incorporated with pre-operative short-term physical therapy and education for MIS-THA. On the other hand, conventional MIS-THA in this study was defined as the conventional pathway without pre-operative physical therapy and education for MIS-THA. Both of ERAS for MIS-THA and conventional MIS-THA comprised the same MIS-THA techniques, multimodal pain control, standardized volume management and PONV prophylaxis, deep vein thrombosis prophylaxis and post-operative rehabilitation program.

Pre-operative physical therapy and education:

Pre-operatively in the outpatient clinics, we informed patients that the discharge days depended on the rehabilitation progress by oral and written information. We also gave patients the detailed information about rehabilitation program and discharge criteria. We consulted physical therapy specialists for one session of physical therapy intervention before operation. The standardized pre-operative physical therapy programs included three parts. First, posterior dislocation precautions were well explained to the patients, including no hip flexion greater than 90 degrees, no hip adduction or hip internal rotation beyond neutral, and no combination of the above motions. Then, therapeutic exercise programs given in acute post-operative inpatient phase were demonstrated and practiced, including ankle pumps, quadriceps sets, gluteal sets, bed-supported knee bends, active hip abduction, and straight leg raising. The patients were instructed to do these exercises by themselves at home until the day of operation. Last, the patients received activity and functional training, including bed mobility, transfer skills, gait training with appropriate assistive device and weight bearing to tolerance, stair training, and modified activities of daily living following precautions.

MIS-THA techniques:

We utilized posterolateral mini-incision techniques with posterior capsulotendinous repair to the posterolateral aspect of greater trochanter bone for every patient receiving MIS-THA. The incision size was routinely 5-8 cm with hip in flexion position based on body build. We did not use surgical drains.

Multimodal pain control:

For post-operative analgesia, we used multimodal pain control protocols including pre-emptive oral analgesics (acetaminophen, celecoxib, tramadol, gabapentin), intra-operative periarticular injection with cocktail mix of analgesics and antibiotics (levobupivacaine, ketorolac, epinephrine, cefazolin), post-operative oral analgesics (acetaminophen, celecoxib, tramadol, gabapentin), and intramuscular ketorolac as needed to control pain without reliance on morphine. Levobupivacaine used in our periarticular injection is a safer analgesic compared with bupivacaine in terms of cardiovascular adverse effects. We did not routinely use patient-controlled analgesia (PCA) pumps containing morphine unless there was a request from the patient.

Standardized volume management and PONV prophylaxis:

For standardized volume management, we used tetrastarch colloid solutions and restrictive strategy of allogenic blood transfusion (hemoglobin < 9 g/dl with altered vital signs or hemoglobin < 7 g/dl without altered vital signs). For PONV prophylaxis and treatment, we used esomeprazole, metoclopramide, ondansetron, and normovolemic fluid control with tetrastarch colloid solutions.

Deep vein thrombosis prophylaxis:

For deep vein thrombosis prophylaxis, we used anti-embolism stockings and daily enoxaparin (40mg) starting from 12 hours after operation for 2 days then oral aspirin for 6 weeks. We used a short-duration anti-thrombotic agent combined with aspirin and early mobilization because the risk of deep vein thrombosis after THA with short-duration pharmacological prophylaxis and early mobilization was quite low. Besides, Asians have a 70% lower prevalence of venous thromboembolism compared to Caucasians.

Post-operative rehabilitation program:

Post-operative rehabilitation program was the same as pre-operative physical therapy and was conducted with close observation of patient's pain tolerance and general conditioning. All patients were discharged direct to their residences without any home-care rehabilitation service.

Discharge criteria:

For ERAS for MIS-THA patients and conventional MIS-THA patients, we used uniform discharge criteria including being self-dependent, being able to walk with crutches or walkers, sufficient pain control with oral analgesics, no infection signs, well knowledge of position restriction, and being able to perform home exercise.

Outcome measures:

A database was established for prospective collection of patient demographic, pre- and post-operative data for statistical analysis. The evaluator was blinded to the grouping of patients in data collection. Primary immediate outcomes were post-operative length of hospital stay and the rate of same-day independent mobilization (ambulation without assistance from another person within 24 hours after operation). Other immediate outcomes included post-operative visual analog scale (VAS) pain scores, analgesics usage, the rate of blood transfusion and PONV. Short-term outcomes were post-operative 1-year Harris hip score, Oxford hip score, and EQ-5D index of self-reported health-related quality of life. We also recorded adverse events as well as hospital cost and profit.

Statistical analysis:

A priori sample size determination was based on post-operative length of hospital stay, which was the primary outcome measure. The sample size was calculated to detect a mean difference of 3 days in post-operative length of stay between ERAS for MIS-THA patients and conventional MIS-THA patients assuming a standard deviation of 3.5 days. We assumed a two-sided type I error of 0.05 and a power of 80%. This resulted in a required sample size of 22 in each group. In this study, we included 50 patients in ERAS group and 25 patients in conventional group, respectively. The case number in this study was sufficient for a priori sample size calculation.

Data are presented as mean ± standard deviation and ratio. Student t-test, Mann-Whitney U test, Chi-square test and Fisher exact test were used to compare continuous or categorical variables between different groups of subjects. Multivariable regression analysis by best subset regression was used to identify significant variables affecting post-operative length of hospital stay. Longitudinal analysis by Generalized Estimating Equations (GEE) using robust standard errors was used to compare repeated measurements such as post-operative VAS pain scores. STATA 11 statistical software (StataCorp LP, College Station, TX, USA) was used for statistical analysis. A two-tailed p value of < 0.05 was considered statistically significant.

Being tested
ERAS for MIS-THA, conventional MIS-THA

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ERAS for MIS-THAProcedure or surgery

    enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)

  • conventional MIS-THAProcedure or surgery

    conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)

Study groups in NCT04145921
Study groupRoleWhat they receive
ERAS for MIS-THAExperimentalenhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
Receives: Procedure: ERAS for MIS-THA
conventional MIS-THAActive comparatorconventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
Receives: Procedure: conventional MIS-THA

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. post-operative length of hospital stay

    post-operative length of hospital stay

    Measured: up to 2 weeks after operation

  2. rate of same-day independent mobilization

    rate of same-day independent mobilization (ambulation without assistance from another person within 24 hours after operation)

    Measured: up to 24 hours after operation

Secondary outcomes (7)
  1. post-operative VAS pain scores

    post-operative visual analog scale (VAS) pain scores

    Measured: up to 24 hours after operation

  2. post-operative analgesics usage

    post-operative analgesics usage

    Measured: up to 2 weeks after operation

  3. the rate of blood transfusion

    the rate of blood transfusion

    Measured: up to 2 weeks after operation

  4. rate of PONV

    rate of post-operative nausea and vomiting (PONV)

    Measured: up to 2 weeks after operation

  5. post-operative 1-year Harris hip score

    post-operative 1-year Harris hip score

    Measured: 1 year after operation

  6. post-operative 1-year Oxford hip score

    post-operative 1-year Oxford hip score

    Measured: 1 year after operation

  7. post-operative 1-year EQ-5D index of quality of life

    post-operative 1-year EQ-5D index of self-reported health-related quality of life

    Measured: 1 year after operation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Oct 2019
  2. Study start7 Jan 2014
  3. Primary completion28 Jun 2016
  4. Study completion28 Aug 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
75 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04145921
Sponsor's protocol ID
201207008RIC
Status last verified
Oct 2019
First submitted
29 Oct 2019
Last updated
31 Oct 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing ERAS for MIS-THA and conventional MIS-THA in people with Total Hip Arthroplasty, run by National Taiwan University Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

post-operative length of hospital stay (time frame: up to 2 weeks after operation). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in